.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AC51_IsoniazidCombinations.IsoniazidCombinations .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AC51_IsoniazidCombinations.IsoniazidCombinations| name: | IsoniazidCombinations | |
| ATC code: | J04AC51 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 0.57 | L |
| clearance: | 19 | L/hr |
| other parameters in model implementation | ||
Isoniazid, in combination with other antimycobacterials (ATC J04AC51), is used for the treatment and prevention of tuberculosis. It is a first-line agent commonly combined with rifampicin, ethambutol, and pyrazinamide. These combinations are approved and remain standard of care for tuberculosis therapy globally.
Estimated pharmacokinetic parameters are given for a typical adult (age 18–65 years, both sexes) receiving isoniazid in combination regimen for tuberculosis; no published compartmental PK model specific to J04AC51 fixed combination product found.